These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study. Nick JA; St Clair C; Jones MC; Lan L; Higgins M; J Cyst Fibros; 2020 Jan; 19(1):91-98. PubMed ID: 31784217 [TBL] [Abstract][Full Text] [Related]
25. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
26. The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report. Johns JD; Rowe SM BMC Gastroenterol; 2019 Jul; 19(1):123. PubMed ID: 31296159 [TBL] [Abstract][Full Text] [Related]
29. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M; Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913 [TBL] [Abstract][Full Text] [Related]
32. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis. Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721 [TBL] [Abstract][Full Text] [Related]
33. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation. Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026 [No Abstract] [Full Text] [Related]
35. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation. Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700 [TBL] [Abstract][Full Text] [Related]
36. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285 [TBL] [Abstract][Full Text] [Related]
37. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients. Bitonti M; Fritts L; So TY J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283 [TBL] [Abstract][Full Text] [Related]
38. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis. Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367 [TBL] [Abstract][Full Text] [Related]
39. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel. Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400 [TBL] [Abstract][Full Text] [Related]
40. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Rosenfeld M; Wainwright CE; Higgins M; Wang LT; McKee C; Campbell D; Tian S; Schneider J; Cunningham S; Davies JC; Lancet Respir Med; 2018 Jul; 6(7):545-553. PubMed ID: 29886024 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]